Literature DB >> 12154400

DNA methylation and gene silencing in cancer: which is the guilty party?

Susan J Clark1, John Melki.   

Abstract

The DNA methylation pattern of a cell is exquisitely controlled during early development resulting in distinct methylation patterns. The tight control of DNA methylation is released in the cancer cell characterized by a reversal of methylation states. CpG island associated genes, in particular tumour suppressor or related genes, are often hypermethylated and this is associated with silencing of these genes. Therefore methylation is commonly convicted as a critical causal event in silencing this important class of genes in cancer. In this review, we argue that methylation is not the initial guilty party in triggering gene silencing in cancer, but that methylation of CpG islands is a consequence of prior gene silencing, similar to the role of methylation in maintaining the silencing of CpG island genes on the inactive X chromosome. We propose that gene silencing is the critical precursor in cancer, as it changes the dynamic interplay between de novo methylation and demethylation of the CpG island and tilts the balance to favour hypermethylation and chromatin inactivation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12154400     DOI: 10.1038/sj.onc.1205598

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  94 in total

1.  Methylation and epigenetic fidelity.

Authors:  Arthur D Riggs; Zhenggang Xiong
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-26       Impact factor: 11.205

2.  Folate deficiency regulates expression of DNA polymerase β in response to oxidative stress.

Authors:  Archana Unnikrishnan; Tom M Prychitko; Hiral V Patel; Mahbuba E Chowdhury; Amanda B Pilling; Lisa F Ventrella-Lucente; Erin V Papakonstantinou; Diane C Cabelof; Ahmad R Heydari
Journal:  Free Radic Biol Med       Date:  2010-11-08       Impact factor: 7.376

3.  Aberrantly silenced promoters retain a persistent memory of the silenced state after long-term reactivation.

Authors:  Jon A Oyer; Phillip A Yates; Sarah Godsey; Mitchell S Turker
Journal:  Mutat Res       Date:  2010-10-28       Impact factor: 2.433

Review 4.  Improved PCR method for amplification of GC-rich DNA sequences.

Authors:  F Hubé; P Reverdiau; S Iochmann; Y Gruel
Journal:  Mol Biotechnol       Date:  2005-09       Impact factor: 2.695

5.  Promoter hypermethylation in Indian primary oral squamous cell carcinoma.

Authors:  Jatinder Kaur; Semra Demokan; Satyendra Chandra Tripathi; Muzafar Ahmad Macha; Shahnaz Begum; Joseph A Califano; Ranju Ralhan
Journal:  Int J Cancer       Date:  2010-11-15       Impact factor: 7.396

6.  Predicting aberrant CpG island methylation.

Authors:  F A Feltus; E K Lee; J F Costello; C Plass; P M Vertino
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-30       Impact factor: 11.205

7.  Prognostic relevance of Period1 (Per1) and Period2 (Per2) expression in human gastric cancer.

Authors:  Han Zhao; Zhao-Lei Zeng; Jing Yang; Ying Jin; Miao-Zhen Qiu; Xiao-Ye Hu; Juan Han; Kai-Yan Liu; Jian-Wei Liao; Rui-Hua Xu; Qing-Feng Zou
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

8.  Comprehensive silencing of target-sharing microRNAs is a mechanism for SIRT1 overexpression in cancer.

Authors:  Kotaro Kiga; Yoko Fukuda-Yuzawa; Masanobu Tanabe; Shoji Tsuji; Chihiro Sasakawa; Taro Fukao
Journal:  RNA Biol       Date:  2014       Impact factor: 4.652

9.  DNA hypermethylation in prostate cancer is a consequence of aberrant epithelial differentiation and hyperproliferation.

Authors:  D Pellacani; D Kestoras; A P Droop; F M Frame; P A Berry; M G Lawrence; M J Stower; M S Simms; V M Mann; A T Collins; G P Risbridger; N J Maitland
Journal:  Cell Death Differ       Date:  2014-01-24       Impact factor: 15.828

10.  Specific gene hypomethylation and cancer: new insights into coding region feature trends.

Authors:  Elias Daura-Oller; Maria Cabre; Miguel A Montero; Jose L Paternain; Antoni Romeu
Journal:  Bioinformation       Date:  2009-04-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.